Medday withdraws licencing application for high dose Biotin

Biotin is an emerging therapy for the treatment of secondary progressive MS.
Post Reply
User avatar
MSUK
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 2:00 pm
Contact:

Medday withdraws licencing application for high dose Biotin

Post by MSUK »

Medday withdraws licencing application for high dose Biotin for progressive MSers

Medday, the makers of Biotin have formally withdrawn their application for EMA (European Medicines Agency) marketing authorisation for progressive MS drug Qizenday...

Read more - http://www.ms-uk.org/medday-withdraws-l ... sive-msers

Image
MS-UK - http://www.ms-uk.org/
User avatar
NHE
Volunteer Moderator
Posts: 6227
Joined: Sat Nov 20, 2004 3:00 pm
Contact:

Re: Medday withdraws licencing application for high dose Bio

Post by NHE »

Dr Frederic Sedel, co-founder and CEO of Medday said: “The decision to withdraw the application was based on the understanding that the EMA was not ready to approve high dose biotin for the treatment of progressive MS based on a single –relatively small- phase III study. This decision means that we will present a much stronger case in the future, based on the results of the ongoing SPI2 study, which is a much larger trial. The SPI2 trial is still looking at patients’ improvement together with decreased progression which is a very ambitious goal. It will also give more information about the subgroups of patients who will benefit the most from the drug, about brain imaging and other measures of efficacy.”
User avatar
jimmylegs
Volunteer Moderator
Posts: 12592
Joined: Sat Mar 11, 2006 3:00 pm

Re: Medday withdraws licencing application for high dose Bio

Post by jimmylegs »

active members shape site content. if there is a problem, speak up!
use the report button to flag problematic post content to volunteer moderators' attention.
Post Reply
  • Similar Topics
    Replies
    Views
    Last post

Return to “Biotin (Qizenday, Cerenday, MD1003)”